MX2009001578A - Lactamas terapeuticas. - Google Patents

Lactamas terapeuticas.

Info

Publication number
MX2009001578A
MX2009001578A MX2009001578A MX2009001578A MX2009001578A MX 2009001578 A MX2009001578 A MX 2009001578A MX 2009001578 A MX2009001578 A MX 2009001578A MX 2009001578 A MX2009001578 A MX 2009001578A MX 2009001578 A MX2009001578 A MX 2009001578A
Authority
MX
Mexico
Prior art keywords
therapeutic
lactams
disclosed
compositions
compound
Prior art date
Application number
MX2009001578A
Other languages
English (en)
Spanish (es)
Inventor
Robert M Burk
David W Old
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2009001578A publication Critical patent/MX2009001578A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2009001578A 2006-08-11 2007-08-09 Lactamas terapeuticas. MX2009001578A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82210806P 2006-08-11 2006-08-11
PCT/US2007/075615 WO2008021975A2 (en) 2006-08-11 2007-08-09 Therapeutic lactams

Publications (1)

Publication Number Publication Date
MX2009001578A true MX2009001578A (es) 2009-02-19

Family

ID=38683367

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001578A MX2009001578A (es) 2006-08-11 2007-08-09 Lactamas terapeuticas.

Country Status (11)

Country Link
US (2) US7482475B2 (enExample)
EP (1) EP2066660A2 (enExample)
JP (1) JP2010500416A (enExample)
KR (1) KR101422305B1 (enExample)
CN (1) CN101522669B (enExample)
AU (1) AU2007286177B2 (enExample)
BR (1) BRPI0716742A2 (enExample)
CA (1) CA2660608A1 (enExample)
MX (1) MX2009001578A (enExample)
NZ (1) NZ597866A (enExample)
WO (1) WO2008021975A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP1996546B1 (en) * 2006-03-20 2014-11-26 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists
WO2008021975A2 (en) * 2006-08-11 2008-02-21 Allergan, Inc. Therapeutic lactams
US7589213B2 (en) * 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
US8440819B2 (en) * 2008-02-22 2013-05-14 Allergan, Inc. Therapeutic substituted beta-lactams
CN102076681A (zh) * 2008-04-24 2011-05-25 阿勒根公司 作为治疗剂的取代γ-内酰胺
WO2014031581A1 (en) * 2012-08-21 2014-02-27 Allergan, Inc. Process for the synthesis of substituted gamma lactams
US20150274658A1 (en) * 2014-03-27 2015-10-01 Allergan, Inc. Therapeutic lactams
HK1249104A1 (zh) 2015-03-13 2018-10-26 Forma Therapeutics, Inc. 作为HDAC8抑制剂的α-肉桂酰胺化合物和组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1991504A (en) * 1928-09-12 1935-02-19 American District Telegraph Co Key-trapping valve lock for transmitter-supervised sprinkler systems
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
NZ535024A (en) * 2002-03-05 2006-10-27 Ono Pharmaceutical Co 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient
AU2003258433A1 (en) 2002-08-28 2004-03-19 Merck Frosst Canada Ltd Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
JP5128954B2 (ja) * 2004-12-06 2013-01-23 メルク セローノ ソシエテ アノニム Dp1受容体アゴニストとして使用されるピロリジン−2−オン誘導体
BRPI0609021A2 (pt) * 2005-03-10 2010-01-12 Allergan Inc gama lactamas substituìdas, composição e uso das mesmas
EP1996546B1 (en) * 2006-03-20 2014-11-26 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists
WO2008021975A2 (en) * 2006-08-11 2008-02-21 Allergan, Inc. Therapeutic lactams

Also Published As

Publication number Publication date
KR101422305B1 (ko) 2014-07-22
KR20090038937A (ko) 2009-04-21
BRPI0716742A2 (pt) 2015-03-24
CN101522669B (zh) 2013-01-16
WO2008021975A2 (en) 2008-02-21
US7482475B2 (en) 2009-01-27
NZ597866A (en) 2013-08-30
JP2010500416A (ja) 2010-01-07
EP2066660A2 (en) 2009-06-10
AU2007286177A1 (en) 2008-02-21
US8686025B2 (en) 2014-04-01
US20080039505A1 (en) 2008-02-14
CN101522669A (zh) 2009-09-02
CA2660608A1 (en) 2008-02-21
WO2008021975A3 (en) 2008-07-10
AU2007286177B2 (en) 2012-06-14
US20090099249A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
MX2009001578A (es) Lactamas terapeuticas.
WO2007135527A3 (en) Benzimidazolyl compounds
MX2010004487A (es) Derivados lactamicos sustituidos y sus usos para glaucoma e hipertension ocular.
DE602007014036D1 (de) 12-aryl-prostaglandin-analoga
TN2011000172A1 (en) Therapeutic antiviral peptides
TNSN08407A1 (en) Organic compounds
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
UA94833C2 (en) Substituted bicyclolactams
TW200714583A (en) Substituted gamma lactams as therapeutic agents
TW200728307A (en) Novel spirochromanone derivatives
UA92637C2 (en) Pyridine[3,4-b]pyrazinones
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
WO2008008718A3 (en) Cyclopentane derivatives as antiglaucoma agents
MY153921A (en) Aminopyrazole derivatives
BRPI0716643A2 (pt) amidas terapêuticas e compostos relacionados
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
TNSN08369A1 (en) Benzimidazole derivatives
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
UA99840C2 (ru) Замещенные циклопентаны, которые имеют простагландиновую активность
MX2009008039A (es) Gamma lactamas substituidas como agentes terapeuticos.
TW200505869A (en) Thiophenylaminoimidazolines
WO2008028032A3 (en) Therapeutic substituted hydantoins and related compounds
MX2009012349A (es) Compuestos de ((fenil)imidazolil)metilheteroarilo.

Legal Events

Date Code Title Description
FG Grant or registration